• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Renal Denervation Devices Market Expected to Reach USD 387 Million by 2032 with a Remarkable 37.2% CAGR, According to Straits Research

    7/16/24 10:20:00 AM ET
    $DVA
    $MDT
    Misc Health and Biotechnology Services
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $DVA alert in real time by email

    New York, United States, July 16, 2024 (GLOBE NEWSWIRE) -- As per the Latest Report by Straits Research, the global renal denervation devices market size was valued at USD 54.26 million in 2023. It is estimated to reach an expected value of USD 387 million by 2032, growing at a CAGR of 37.2% during the forecast period (2024–2032).

    A minimally invasive treatment called renal denervation is used to treat resistant hypertension. The primary contributors to the growth of the renal denervation devices market are the increasing elderly population, the rising prevalence of hypertension, and the procedure's long-lasting effects. 

    Download Free Sample Report PDF @ https://straitsresearch.com/report/renal-denervation-devices-market/request-sample

    Rising Prevalence of Hypertension Propels the Renal Denervation Devices Market

    The prevalence of hypertension-related illnesses and chronic conditions continues to increase globally. Hypertension, commonly known as high blood pressure, is a severe medical condition that significantly raises the chance of developing heart, kidney, brain, and other disorders. In 2018, the Centers for Disease Control and Prevention (CDC) reported that high blood pressure was a primary cause of death for more than 494,873 Americans, with over 100 million suffering from the illness. An increase in hypertension cases is anticipated to generate demand for renal denervation devices during the projected period.

    According to the United Nations Department of Economics and Social 2019 report, it was estimated that by the year 2050, 16% of the global population would be over 65, up from 9% in 2019. By 2050, one in four people in Europe and Northern America could be 65 or older. In 2018, people aged 65 and over outnumbered children under five globally for the first time in history. The number of people aged 80 and older is anticipated to treble between 2019 and 2050, from 143 million to nearly 426 million. The percentage of the population aged 65 or older virtually doubled from 6% in 1990 to 11% in 2019 in Eastern and South-Eastern Asia and from 5% in 1990 to 9% in 2019 in Latin America and the Caribbean, according to the same survey. In four regions, namely Central and Southern Asia, Northern Africa and Western Asia, Eastern and South-Eastern Asia, and Latin America and the Caribbean, the percentage of the elderly is anticipated to quadruple.

    It is anticipated that the number of individuals suffering from hypertension will increase as the global population ages. Hypertension is caused by aging-related arterial stiffness, hemodynamic alterations, neurohormonal and autonomic dysregulation, and diminishing the renal function. Consequently, all of the considerations mentioned above suggest that an increase in hypertension cases would drive demand for renal denervation devices over the projection period, thereby boosting the growth of the analyzed market.

    Groundbreaking Research Creates Untapped Market Potential

    Innovative research in fields such as hypertension has also led to the expansion of new commercial prospects. In February 2020, Ablative Solutions, Inc. published favorable research results regarding the safety and efficacy of its CE-marked Peregrine System Infusion Catheter. The study determined that the renal denervation treatment utilizing the Peregrine Catheter and alcohol as a neurolytic agent is safe and effective and can reduce blood pressure in patients with poorly managed hypertension on medication.

    The number of firms shaping the future of Renal Denervation Devices is increasing. As the healthcare industry pushes toward minimally invasive surgeries, a growing interest is in developing solutions for hypertension treatment, which is projected to lead to market growth. Future growth potential for the market for denervation devices is likely to be significantly influenced by the reasons mentioned above.

    Regional Insights

    Europe accounts for the largest market share and is estimated to grow at a CAGR of 37.5% during the forecast period. The growth is attributable to the rising geriatric population. The spiking cases of therapy-resistant hypertension are also a key factor driving the market. Hypertension is one of the most common diseases in Europe. Changes in lifestyle, such as excessive alcohol consumption, lack of physical activity, smoking, and consumption of fast food, increase the risk of hypertension. The increased blood pressure subsequently gives rise to various diseases, such as stroke, heart attacks, and pulmonary arterial hypertension. The increasing prevalence of smoking in Germany is also causing hypertension, increasing the demand for renal denervation devices. 

    Asia-Pacific is estimated to account for USD 90 million by 2030, registering a CAGR of 37.6%. The market is anticipated to expand in the region because of the rising prevalence of hypertension and increasing awareness of the treatment's benefits. Renal denervation can selectively ablate renal sympathetic nerve fibers and prevent the transmission of nerve impulses between the central sympathetic nerve and kidney to control blood pressure as a unique, promising non-drug therapeutic option for hypertension resistant to drug therapy. Increasing research into the treatment's efficacy is the primary driver of the anticipated market expansion. Therefore, the increasing prevalence of hypertension and cardiovascular disorders increases the desire for appropriate treatment, raising the country's demand for the devices.

    North America is the third largest region. The increasing prevalence of hypertension, the changing lifestyle, the growing senior population, and the long-lasting effect of the surgery may lead to a sharp increase in demand. Domestic enterprises are employing numerous techniques to increase their market position, including R&D, mergers and acquisitions, and product launches. In 2020, the US-based company ReCor Medical Inc. announced that it is Paradise Ultrasound Renal Denervation System has achieved Breakthrough Device Designation from the FDA. The renal nerve is ablated using ultrasonic energy using the Paradise system. Consequently, the increasing prevalence of hypertension, the ongoing development of the industry, and the adoption of new technologies by market participants in the country are anticipated to stimulate the expansion of the market under study.

    To Gather Additional Insights on the Regional Analysis of the Renal Denervation Devices Market @ https://straitsresearch.com/report/renal-denervation-devices-market/request-sample

    Key Highlights

    • The global renal denervation devices market size is estimated to reach an expected value of USD 387 million by 2032, growing at a CAGR of 37.2% during the forecast period (2024–2032).
    • By technology, the global renal denervation devices market is segmented into Radiofrequency-based, Ultrasound-based, and Micro-infusion-based. Radiofrequency-based accounts for the largest market share and is estimated to grow at a CAGR of 37.1% during the forecast period.

    Competitive Players

    1. Medtronic PLC
    2. St. Jude Medical Inc. (Abbott Laboratories)
    3. ReCor Medical Inc. (Otsuka Holdings Co. Ltd)
    4. Ablative Solutions Inc.
    5. Mercator MedSystems Inc.
    6. Terumo Corporation
    7. Symple Surgical Inc.
    8. Vessix Vascular Inc. (Boston Scientific Corporation)
    9. Johnson & Johnson Private Limited
    10. Kona Medical Inc.
    11. Renal Dynamics Limited
    12. Covidien PLC
    13. DeepQure
    14. SoniVie (CardioSonic, Inc.)
    15. Miracor Medical SA

    Recent Developments

    • July 2022 - Medtronic expanded Health Equity Assistance Program for colon cancer screening with support from Amazon Web Services; Completed the first installation of donated GI Genius™ intelligent endoscopy modules. 
    • July 2022 - Medtronic received FDA clearance for next-generation UNiD™ Spine Analyzer with degenerative spine surgery predictive model. 
    • May 2022 - Medtronic plc (opens new window) (NYSE:MDT) and DaVita Inc. (opens new window) (NYSE:DVA) announced the intent to form a new, independent kidney care-focused medical device company ("NewCo" or "the Company") to enhance the patient treatment experience and improve overall outcomes. 

    Market Segmentation

    1. By Technology
      1. Radiofrequency-based
      2. Ultrasound-based
      3. Micro-infusion-based
      4. Others
    2. By End User
      1. Hospitals & Clinics
      2. Ambulatory surgery centers
      3. Others
    3. By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East and Africa

    Get Detailed Market Segmentation @ https://straitsresearch.com/report/renal-denervation-devices-market/segmentation

    About Straits Research Pvt. Ltd.

    Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

    Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client's purchase. We overcome our clients' issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

    For more information on your target market, please contact us below:

    Phone: +1 646 905 0080 (U.S.)

    +91 8087085354 (India)

    +44 203 695 0070 (U.K.)

    Email: [email protected]

    Follow Us: LinkedIn | Facebook | Instagram | Twitter



    Primary Logo

    Get the next $DVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVA
    $MDT

    CompanyDatePrice TargetRatingAnalyst
    Medtronic plc.
    $MDT
    2/13/2026$116.00Overweight
    Barclays
    Medtronic plc.
    $MDT
    2/9/2026$121.00Hold → Buy
    Needham
    Medtronic plc.
    $MDT
    2/3/2026$117.00Buy
    Citigroup
    Medtronic plc.
    $MDT
    1/30/2026$114.00Overweight
    Wells Fargo
    Medtronic plc.
    $MDT
    1/6/2026Mkt Perform → Outperform
    William Blair
    Medtronic plc.
    $MDT
    11/19/2025$111.00Sell → Neutral
    Goldman
    Medtronic plc.
    $MDT
    6/30/2025Underperform → Peer Perform
    Wolfe Research
    Medtronic plc.
    $MDT
    6/16/2025$110.00Outperform
    Leerink Partners
    More analyst ratings

    $DVA
    $MDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Medtronic with a new price target

    Barclays resumed coverage of Medtronic with a rating of Overweight and set a new price target of $116.00

    2/13/26 8:31:53 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic upgraded by Needham with a new price target

    Needham upgraded Medtronic from Hold to Buy and set a new price target of $121.00

    2/9/26 6:45:10 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Citigroup resumed coverage on Medtronic with a new price target

    Citigroup resumed coverage of Medtronic with a rating of Buy and set a new price target of $117.00

    2/3/26 6:56:06 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $DVA
    $MDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jellison William R bought $462,750 worth of Ordinary Shares (5,000 units at $92.55) (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/25/25 5:18:06 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $DVA
    $MDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Arway Pamela M was granted 332 shares, increasing direct ownership by 1% to 26,695 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:27 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Desoer Barbara J was granted 332 shares (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:18 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Chief Operating Officer, DKC Maughan David Paul was granted 5,308 shares and covered exercise/tax liability with 13,107 shares, decreasing direct ownership by 6% to 114,467 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:04 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    $MDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medtronic OmniaSecure™ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing

    Built for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecure™ defibrillation lead. Now approved for placement in the left bundle branch (LBB) area, the lead can be used for conduction system pacing (CSP), which closely mimics the heart's natural physiology. Additionally, patients in need of cardiac resynchronization may benefit from left bundle branch optimized cardiac resynchronization therapy (LOT-CRT), a nove

    3/23/26 9:00:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement

    Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.DENVER, March 18, 2026 /PRNewswire/ -- DaVita today highlighted continued progress in value-based kidney care, underscoring how sustained investment in coordinated care models is translating into improved outcomes for people living with kidney disease. That progress is evident across both industry partnerships with major insurers and scaled programs sponsored by the Center for Medicare & Medicaid Innovation (CMMI).For more than two dec

    3/18/26 3:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

    AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysisAlebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therapeutics, a newly launched company backed by leading global kidney care providers and life sciences strategic and venture capital investorsThe collaboration includes potential milestone payments of up to low triple-digit millions of U.S. dollars and tiered royalties in the low double-digit percentage range based on net sales of AP306 in the licensed territoryAlebund holds a substantial non-dilutive equit

    3/17/26 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    $MDT
    SEC Filings

    View All

    SEC Form 10-Q filed by Medtronic plc.

    10-Q - Medtronic plc (0001613103) (Filer)

    2/24/26 4:18:20 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Medtronic plc (0001613103) (Filer)

    2/17/26 6:48:07 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by DaVita Inc.

    10-K - DAVITA INC. (0000927066) (Filer)

    2/11/26 4:06:39 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    $MDT
    Leadership Updates

    Live Leadership Updates

    View All

    Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

    GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

    7/8/25 8:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic Board appoints Dr. Joon Lee as a new director

    GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

    6/23/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

    NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

    3/31/25 4:21:30 PM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $DVA
    $MDT
    Financials

    Live finance-specific insights

    View All

    Medtronic announces cash dividend for fourth quarter of fiscal year 2026

    GALWAY, Ireland, March 5, 2026 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 5, 2026, approved the company's cash dividend for the fourth quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on April 17, 2026, to shareholders of record at the close of business on March 27, 2026.About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquarte

    3/5/26 4:53:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters

    Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolioGALWAY, Ireland, Feb. 17, 2026 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its third quarter (Q3) of fiscal year 2026 (FY26), which ended January 23, 2026.Q3 Key HighlightsRevenue of $9.0 billion, increased 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidanceGAAP diluted EPS of $0.89; non-GAAP diluted EPS of $1.36, three cents ahead of Q3 guidance mid-pointCompany reiterates FY26 organic revenue growth and EPS guidanceCardiac Ablation Solutions revenue increased 80%, includin

    2/17/26 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    DaVita Inc. 4th Quarter 2025 Results

    DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita. "Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond." Financial and operating highlights for the quarter and year ended December 31, 2025: Consolidated revenues were $3.620 billion

    2/2/26 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    $MDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/13/24 5:09:43 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/13/24 5:02:42 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/12/24 1:59:55 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care